North Carolina is currently home to 2641 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Fertilo In Vitro Research Study and Trial
NCT06858111
Recruiting
The goal of this clinical trial is to evaluate the safety and efficacy of using Fertilo for In vitro maturation (IVM) in participants 18-35 years of age. The main question it aims to answer is whether the use of Fertilo is superior to using Medicult IVM for In vitro maturation. Researchers will compare the number of ongoing pregnancies at 12 weeks gestation for participants in each arm. * Arm 1 participants will have all cumulus oocyte complexes (COCs), or eggs surrounded by helper cells, cult... Read More
Gender:
FEMALE
Ages:
Between 18 years and 35 years
Trial Updated:
07/16/2025
Locations: Reach Fertility, Charlotte, North Carolina
Conditions: In Vitro Maturation of Oocytes
Register for Updates
A Study of NE3107 in Early Parkinson's
NCT06757010
Recruiting
The goal of this clinical trial is to learn if bezisterim can treat movement symptoms of Parkinson's disease in patients that are 45 to 80 years old, in generally good physical and mental health, and are nearing the need for treatment to relieve their symptoms but have not yet been prescribed any form of levodopa or drug with similar activity. The main questions it aims to answer are: * Will bezisterim decrease movement symptoms of Parkinson's disease? * What medical problems do participants ha... Read More
Gender:
ALL
Ages:
Between 45 years and 80 years
Trial Updated:
07/16/2025
Locations: Science 37 (Nationwide Site), Morrisville, North Carolina
Conditions: Parkinsons Disease (PD)
Register for Updates
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
NCT06694805
Recruiting
This study will assess how effective, safe, and long-lasting a long-acting antiretroviral therapy (ART) using CAB LA + RPV LA is for people with HIV who still have detectable virus levels despite being on oral ART. The study will also consider feedback from patients on their experience with this treatment.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/16/2025
Locations: GSK Investigational Site, Greensboro, North Carolina
Conditions: HIV Infections
Register for Updates
Postoperative Radiotherapy for Intermediate- and High-risk Patients With HNSCC Greater Than 6 Weeks After Surgery
NCT06607406
Recruiting
The goal of this clinical trial is to determine whether accelerated radiotherapy (involving 6 treatments per week) is better than standard radiotherapy (involving 5 treatments per week) at treating cancer of the head and neck when initiated more than 6 weeks after surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma HNSCC
Register for Updates
CROSSOVER STUDY OF ON-DEMAND PREP FORMULATIONS COMPARING RECTAL AND ORAL TENOFOVIR
NCT06560684
Recruiting
This is a Phase 2, multi-site, two-period, open label randomized crossover (Period 1 and 2) study. Participants are randomized 1:1 to one of two 8-week on-demand product sequences - TFV douche then oral F/TDF or oral F/TDF then TFV douche - with a 2 to 4-week washout period in between. Domains of safety, acceptability, adherence, and PK/PD (sub-study only) are assessed for each product.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Chapel Hill CRS (3201), Chapel Hill, North Carolina
Conditions: Tenofovir
Register for Updates
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
NCT06555796
Recruiting
The main objective of this study is to evaluate the safety and tolerability of xaluritamig monotherapy in adult participants with high-risk biochemical recurrent (BCR) nonmetastatic castration-sensitive prostate cancer (nmCSPC).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Prostate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, Non-metastatic Castration-sensitive Prostate Cancer
Register for Updates
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
NCT06553768
Recruiting
The purpose of this study is to determine whether the investigational treatment (maralixibat) is safe and effective in pediatric and adult participants who have cholestatic liver disease with pruritus that has been refractory to other therapies, and who have no other treatment options.
Gender:
ALL
Ages:
6 months and above
Trial Updated:
07/16/2025
Locations: Science 37, Inc (Remote-homebase Telemedicine), Morrisville, North Carolina
Conditions: Cholestatic Liver Disease (except ALGS, PFIC, PBC and PSC)
Register for Updates
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
NCT06525220
Recruiting
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Site 113, Durham, North Carolina
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
NCT06523621
Recruiting
This study is designed to evaluate if treatment with adjuvant nivolumab improves depth of response in patients with relapsed refractory multiple myeloma (RRMM) who achieve a less-than-ideal response to idecaptagene vicleucel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Multiple Myeloma
Register for Updates
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
NCT06305767
Recruiting
Researchers are looking for new ways to treat people with high-risk muscle-invasive urothelial carcinoma (MIUC). Urothelial carcinoma is a type of bladder cancer that begins in cells that line the inside of the bladder and other parts of the urinary tract, such as part of the kidneys, ureters, and urethra. People with MIUC usually have chemotherapy before surgery, then surgery to remove the cancer. Chemotherapy is a type of medicine to destroy cancer cells or stop them from growing. After surger... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Duke Cancer Institute ( Site 0107), Durham, North Carolina
Conditions: Bladder Cancer
Register for Updates
WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment
NCT06291324
Recruiting
The purpose of this study is to evaluate the feasibility of using a commercial WATD (Wearable Activity Tracker Device) to collect HRV (Heart Rate Variability) data from pancreatic and breast cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Pancreatic Cancer, Breast Cancer
Register for Updates
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
NCT06154837
Recruiting
The primary objective of the study is to investigate the safety and tolerability of ascending doses of GSK3862995B following single dose in healthy participants and repeat doses in participants with Chronic obstructive pulmonary disease (COPD).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/16/2025
Locations: GSK Investigational Site, Shelby, North Carolina
Conditions: Pulmonary Disease, Chronic Obstructive
Register for Updates